Foghorn Therapeutics Q2 collaboration revenue rises, loss narrows

Reuters

Aug 05

Foghorn <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> collaboration revenue rises, loss narrows

Overview

Foghorn Therapeutics Q2 collaboration revenue rises to $7.6 mln, driven by Lilly partnership
Net loss for Q2 decreases to $17.9 mln compared to $23.0 mln last year
Co maintains strong cash position with $198.7 mln, runway into 2028

Outlook

Company has cash runway into 2028
FHD-909 Phase 1 trial remains on track

Result Drivers

FHD-909 TRIAL - Phase 1 trial for SMARCA4-mutated cancers enrolling well, per CEO Adrian Gottschalk
SYNERGISTIC DATA - Preclinical data shows FHD-909 enhances anti-tumor activity with pembrolizumab and KRAS inhibitors
DEGRADER PROGRAMS - Progress in selective CBP, EP300, and ARID1B degrader programs with updates expected in Q4 2025

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Collaboration Revenue		$7.56 mln
Q2 EPS		-$0.28
Q2 Net Income		-$17.94 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Foghorn Therapeutics Inc is $11.50, about 55.3% above its August 4 closing price of $5.14

Press Release: ID:nGNX7pCXN1

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557763395"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557763395\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557763395?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557763395","market":"nz","top_or_hot":-1,"title":"Foghorn Therapeutics Q2 collaboration revenue rises, loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Foghorn <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> collaboration revenue rises, loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Foghorn Therapeutics Q2 collaboration revenue rises to $7.6 mln, driven by Lilly partnership</p></li><li><p>Net loss for Q2 decreases to $17.9 mln compared to $23.0 mln last year</p></li><li><p>Co maintains strong cash position with $198.7 mln, runway into 2028</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company has cash runway into 2028</p></li><li><p>FHD-909 Phase 1 trial remains on track</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FHD-909 TRIAL - Phase 1 trial for SMARCA4-mutated cancers enrolling well, per CEO Adrian Gottschalk</p></li><li><p>SYNERGISTIC DATA - Preclinical data shows FHD-909 enhances anti-tumor activity with pembrolizumab and KRAS inhibitors</p></li><li><p>DEGRADER PROGRAMS - Progress in selective CBP, EP300, and ARID1B degrader programs with updates expected in Q4 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Collaboration Revenue</p></td><td></td><td><p>$7.56 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$17.94 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Foghorn Therapeutics Inc is $11.50, about 55.3% above its August 4 closing price of $5.14</p></li></ul><p>Press Release: <span>ID:nGNX7pCXN1</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Foghorn Therapeutics Q2 collaboration revenue rises, loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFoghorn Therapeutics Q2 collaboration revenue rises, loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-05 19:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Foghorn <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> collaboration revenue rises, loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Foghorn Therapeutics Q2 collaboration revenue rises to $7.6 mln, driven by Lilly partnership</p></li><li><p>Net loss for Q2 decreases to $17.9 mln compared to $23.0 mln last year</p></li><li><p>Co maintains strong cash position with $198.7 mln, runway into 2028</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company has cash runway into 2028</p></li><li><p>FHD-909 Phase 1 trial remains on track</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FHD-909 TRIAL - Phase 1 trial for SMARCA4-mutated cancers enrolling well, per CEO Adrian Gottschalk</p></li><li><p>SYNERGISTIC DATA - Preclinical data shows FHD-909 enhances anti-tumor activity with pembrolizumab and KRAS inhibitors</p></li><li><p>DEGRADER PROGRAMS - Progress in selective CBP, EP300, and ARID1B degrader programs with updates expected in Q4 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Collaboration Revenue</p></td><td></td><td><p>$7.56 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$17.94 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Foghorn Therapeutics Inc is $11.50, about 55.3% above its August 4 closing price of $5.14</p></li></ul><p>Press Release: <span>ID:nGNX7pCXN1</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FHTX","symbol_name":"Foghorn Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nPLX8C5374:2","article_id":"2557763395","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557763395","pubTimestamp":1754392358,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Foghorn Therapeutics Q2 collaboration revenue rises, loss narrowsOverviewFoghorn Therapeutics Q2 collaboration revenue rises to $7.6 mln, driven by Lilly partnershipNet loss for Q2 decreases to $17.9 ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FHTX":"Foghorn Therapeutics Inc."},"translate_title":"Foghorn Therapeutics第二季度合作收入上升，亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FHTX":0.9},"content_text":"Foghorn Therapeutics Q2 collaboration revenue rises, loss narrowsOverviewFoghorn Therapeutics Q2 collaboration revenue rises to $7.6 mln, driven by Lilly partnershipNet loss for Q2 decreases to $17.9 mln compared to $23.0 mln last yearCo maintains strong cash position with $198.7 mln, runway into 2028OutlookCompany has cash runway into 2028FHD-909 Phase 1 trial remains on trackResult DriversFHD-909 TRIAL - Phase 1 trial for SMARCA4-mutated cancers enrolling well, per CEO Adrian GottschalkSYNERGISTIC DATA - Preclinical data shows FHD-909 enhances anti-tumor activity with pembrolizumab and KRAS inhibitorsDEGRADER PROGRAMS - Progress in selective CBP, EP300, and ARID1B degrader programs with updates expected in Q4 2025Key DetailsMetricBeat/MissActualConsensus EstimateQ2 Collaboration Revenue$7.56 mlnQ2 EPS-$0.28Q2 Net Income-$17.94 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Foghorn Therapeutics Inc is $11.50, about 55.3% above its August 4 closing price of $5.14Press Release: ID:nGNX7pCXN1(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}